Sobi - Swedish Orphan Biovitrum AB (publ)

We’re excited to kick off Compliance Week from 4 to 8 November at Sobi.  This important week is dedicated to promoting ethical behavior, maintaining legal standards, and fostering a culture of integrity across our organisation. Throughout the week and across all locations, we will host a variety of internal activities for our employees to reinforce our collective commitment to compliance, ethics, and integrity. But Compliance Week is more than just events - it’s a vital part of who we are as a company. By staying informed and vigilant, we maintain the integrity and trust that patients, partners and stakeholders expect from us every day. For us, compliance isn’t just a checkbox - it’s a mindset that drives organisational integrity and resilience. Let’s make this week memorable, engaging, and impactful, as we reinforce our shared commitment in doing the right thing for people living with rare and debilitating diseases and for the broader community.   #Sobi #RareDiseases #DoingTheRightThing #ComplianceWeek2024

On 1 November, we shine a light on Familial Chylomicronemia Syndrome (FCS), an ultra-rare genetic disorder that affects the body’s ability to process triglycerides, leading to a build-up of fat particles in the blood. While high triglyceride levels are something many people encounter during routine health check-ups, for some, it could be a sign of FCS. This condition can cause severe symptoms such as intense abdominal pain, cognitive difficulties, and an enlarged liver or spleen. One of the most serious risks for people with FCS is acute pancreatitis – a potentially life-threatening complication. Early diagnosis is crucial in reducing these risks, but FCS often goes undiagnosed due to its similarities with other conditions. Join us in raising awareness this FCS Awareness Day to help improve early detection and treatment for those affected. Are you a healthcare professional interested in learning more about FCS? Click for information tailored to your needs.  https://lnkd.in/dAw3yv3J #Sobi #RareDisease #FCSAwarenessDay #FamilialChylomicronemiaSyndrome #Hypertriglyceridemia 

We are excited to share our third quarter results, showcasing strong growth and significant pipeline momentum. Our growth continued at 39% at CER and the adjusted EBITA margin was 43%. "Our solid growth trajectory was sustained in the third quarter, and we continued to deliver on our clinical development milestones," says Guido Oelkers, President & CEO. We are optimistic for the rest of the year and building on this momentum. Our advancements highlight our dedication to improving the lives of those affected by rare and debilitating diseases. Explore the full report: https://lnkd.in/dvd6buHC #Sobi #RareDiseases #InvestorRelations

Celebrating Global Diversity Awareness Month. At Sobi, we believe that diversity goes beyond what meets the eye. This month, we are proud to shine a spotlight on neurodiversity - embracing different ways of thinking, learning, and working. Neurodiversity recognises the natural variations in brain function and behaviour, including conditions such as autism, ADHD, and dyslexia. It’s about understanding that neurological differences should be respected, just like any other human variation. Creating an inclusive workplace culture where everyone feels valued is essential, especially in today’s hybrid work environment. Through interactive workshops, we are integrating Diversity, Equity, and Inclusion (DEI) into our ways of working, promoting engagement and collaboration. We remain committed to fostering a culture that values and celebrates all forms of diversity - because by embracing our differences, we become stronger as a team. #Sobi #RareDiseases #InclusiveWorkplace #GlobalDiversityAwarenessMonth

Today, we unite to raise awareness for Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and life-threatening blood disorder. PNH affects the red blood cells, leading to severe symptoms and complications. This year, we are proud to highlight the Stories of Strength campaign, created in collaboration with people living with PNH. This campaign shines a light on the incredible resilience and courage of those facing this disease. Their stories continue to inspire us to advocate for better treatments and more support. Anna’s fictionalised story is inspired by a real person living with PNH. There were days when Anna felt a positive future was out of reach. However, she shared, “I was never alone. With the support of my doctors, friends, and family, I found an inner strength, and joy has returned to my life.” Visit https://lnkd.in/d2tVWfBh to hear Anna share her journey from diagnosis to treatment and how she reignited her strength and passions. Let’s come together to support those living with PNH and their families. Together, we can make a difference! #Sobi #RareDiseases #PNHAwareness2024 #Storiesofstrength

From brewing roots to global biopharmaceutical leadership – discover Sobi's legacy. Our history is a story of challenges overcome. From our Swedish origins, we have grown into an international biopharmaceutical leader, present in 30 countries and delivering medicines worldwide. Our rich heritage of collaborative expertise has empowered us to identify and develop innovative medicines consistently. We are dedicated to addressing significant unmet medical needs and transforming the lives of people living with rare and debilitating diseases. Explore our history and learn more about our journey. https://lnkd.in/dwcwATGv

Spotlight on Paroxysmal Nocturnal Haemoglobinuria, PNH, a rare blood disease that can have a profound impact on patients’ lives. It is caused by mutations in the cells responsible for producing red blood cells, which are essential for oxygen transport in the body. These mutations lead to the production of defective blood cells, triggering the immune system to attack and destroy them. This is the main cause of PNH symptoms and complications. This rare condition can affect anyone, regardless of age, race, or gender, yet no one is born with PNH. At Sobi, we are dedicated to raising awareness about rare diseases like PNH. Visit our website to learn more about the disease. https://lnkd.in/dA6JHXCm #Sobi #RareDiseases #PNH #PNHAwareness

This year’s European Haemophilia Consortium (EHC) Conference 2024 starts today! At Sobi, we’re committed to transforming the lives of people with rare and debilitating diseases and we are excited to participate once again at the EHC Conference 2024 in Sofia, Bulgaria. We look forward to participating in discussions on improving care for people living with haemophilia. You are invited to visit us at our booth! #Sobi #RareDiseases #EHC2024 #BleedingDisorders

We’re proud to celebrate 10 years of collaboration with Sanofi and the World Federation of Hemophilia Humanitarian Aid Program. Together, we’re working to bridge the gap in care in under-resourced regions and over the past decade we’ve had the privilege of touching countless lives around the globe. This year our team witnessed the impact of this initiative firsthand on a trip to India, where comprehensive haemophilia care has transformed the lives of many. Learn more about the journey and the inspiring stories of resilience from patients and caregivers: https://lnkd.in/dBTWgSx9 #Sobi #RareDiseases #TreatmentForAll #haemophilia

We have moved! Yesterday, Sobi officially opened the doors to our new global headquarters in the Fenix Sthlm building in Hagastaden, Stockholm, Sweden. Our new office places us in a thriving healthcare and life sciences environment, close to Sweden’s largest hospital and key research institutions. This move marks an important milestone for us, providing a modern, open workspace designed to foster collaboration and innovation as we continue our mission of transforming the lives of people with rare diseases. We are excited for the future and all that we will accomplish from our new headquarters! #Sobi #RareDiseases #Innovation